The Journal of Allergy and Clinical Immunology
Volume 120, Issue 6 , Pages 1413-1417 , December 2007

The natural history of egg allergy

Received 28 June 2007 ,Revised 12 September 2007 ,Accepted 17 September 2007.

  • Image Result

    Egg allergy resolution over time. Graphs represent Kaplan-Meier survival curves for development of tolerance to egg over time using 3 definitions for tolerance.

    Egg allergy resolution over time. Graphs represent Kaplan-Meier survival curves for development of tolerance to egg over time using 3 definitions for tolerance.

  • Image Result

    Trend in egg IgE levels over time by final egg allergy status. Scatter plots of all egg IgE levels recorded by age (n = 2681). A, All values in the group with persistent egg allergy (n = 2192). B, All

    Trend in egg IgE levels over time by final egg allergy status. Scatter plots of all egg IgE levels recorded by age (n = 2681). A, All values in the group with persistent egg allergy (n = 2192). B, All values in the group that eventually resolved egg allergy (n = 489). Nonparametric smoothed curves show the trend in egg IgE levels over time.

  • Image Result
    Relationship of peak egg IgE level and resolution of egg allergy. Survival curves for each stratum of peak egg IgE level. Number of patients in each stratum: <2 kU/L (n = 155); 2-4.9 (n = 131); 5-9.9

    Relationship of peak egg IgE level and resolution of egg allergy. Survival curves for each stratum of peak egg IgE level. Number of patients in each stratum: <2 kU/L (n = 155); 2-4.9 (n = 131); 5-9.9 (n = 125); 10-19.9 (n = 118); 20-49.9 (n = 103); 50+ (n = 162). Number of patients remaining at the final time point analyzed for each stratum: <2 kU/L (n = 3); 2-4.9 (n = 3); 5-9.9 (n = 3); 10-19.9 (n = 2); 20-49.9 (n = 1); 50+ (n = 1).

 Supported by the Food Allergy Initiative, Julie and Neil Reinhard, and the Eudowood Foundation.

 Disclosure of potential conflict of interest: R. A. Wood has consulting arrangements with Dey Pharmaceuticals, has received grant support from Genentech and Merck, and is on the speakers' bureau for GlaxoSmithKline, Merck, and Dey. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(07)01834-9

doi: 10.1016/j.jaci.2007.09.040

The Journal of Allergy and Clinical Immunology
Volume 120, Issue 6 , Pages 1413-1417 , December 2007